newsfilter
← Latest News
GlobeNewswire·

Braveheart Bio to Participate in the Jefferies Global Healthcare Conference in London

  • Braveheart Bio, Inc. (Nasdaq: BRVE) will participate in the Jefferies Global Healthcare Conference in London from November 16-19, 2026.
  • Company management will hold a fireside chat on Wednesday, November 18, 2026, at 1:30 p.m. GMT / 8:30 a.m. ET.
  • A live webcast will be available via the News & Events section of the Braveheart Bio website, with a replay accessible in a temporary archive after the event.
  • The company is developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) & other serious cardiovascular diseases.
  • Lead product candidate BHB-1893 is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for obstructive HCM (oHCM) & non-obstructive HCM (nHCM).
  • BHB-1893 aims to address current CMI limitations by offering rapid onset, consistent response depth, preserved systolic function, prompt reversibility, & straightforward titration.
  • Investor inquiries should contact Alexander Sharif at New Street Investor Relations.
  • Media inquiries should contact FGS Global.
Company
Braveheart Bio, Inc.
Keywords
Nasdaq:BRVE, Braveheart Bio, Inc., biotechnology, cardiology, cardiomyopathy, pharmaceuticals